131 related articles for article (PubMed ID: 16885749)
1. Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy.
Mehrotra P; Gonzalez MA; Johnson SJ; Coleman N; Wilson JA; Davies BR; Lennard TW
Laryngoscope; 2006 Aug; 116(8):1434-8. PubMed ID: 16885749
[TBL] [Abstract][Full Text] [Related]
2. Role of Ki-67 as a proliferative marker in lesions of thyroid.
Pujani M; Arora B; Pujani M; Singh SK; Tejwani N
Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907
[TBL] [Abstract][Full Text] [Related]
3. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
5. Significance of AgNORs and ki-67 proliferative markers in differential diagnosis of thyroid lesions.
Aiad HA; Bashandy MA; Abdou AG; Zahran AA
Pathol Oncol Res; 2013 Apr; 19(2):167-75. PubMed ID: 23055017
[TBL] [Abstract][Full Text] [Related]
6. Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance.
Shomori K; Nishihara K; Tamura T; Tatebe S; Horie Y; Nosaka K; Haruki T; Hamamoto Y; Shiomi T; Nakabayashi M; Ito H
Gastric Cancer; 2010 Aug; 13(3):177-85. PubMed ID: 20820987
[TBL] [Abstract][Full Text] [Related]
7. [Role of the MIB-1 proliferative markers in the diagnosis and prognosis of tumors of the thyroid gland].
Ludvíková M; Ryska A; Hovorková E; Pikner R
Cesk Patol; 2002 Jan; 38(1):4-10. PubMed ID: 11933461
[TBL] [Abstract][Full Text] [Related]
8. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
9. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
10. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity.
Giaginis C; Georgiadou M; Dimakopoulou K; Tsourouflis G; Gatzidou E; Kouraklis G; Theocharis S
Dig Dis Sci; 2009 Feb; 54(2):282-91. PubMed ID: 18465232
[TBL] [Abstract][Full Text] [Related]
12. Significance of IMP3, nucleophosmin, and Ki-67 expression in papillary thyroid carcinoma.
Yorukoglu A; Yalcin N; Avci A; Cakalagaoglu F; Yaylali G; Akin F; Haciyanli M; Ozden A
Int J Surg Pathol; 2015 Feb; 23(1):5-12. PubMed ID: 25389240
[TBL] [Abstract][Full Text] [Related]
13. Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance.
Tokuyasu N; Shomori K; Nishihara K; Kawaguchi H; Fujioka S; Yamaga K; Ikeguchi M; Ito H
Gastric Cancer; 2008; 11(1):37-46. PubMed ID: 18373176
[TBL] [Abstract][Full Text] [Related]
14. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers.
Wojnar A; Kobierzycki C; Krolicka A; Pula B; Podhorska-Okolow M; Dziegiel P
Folia Histochem Cytobiol; 2010 Sep; 48(3):442-6. PubMed ID: 21097442
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
17. MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland.
Rickert D; Mittermayer C; Lindenfelser R; Biesterfeld S
Anal Quant Cytol Histol; 2000 Jun; 22(3):229-34. PubMed ID: 10872040
[TBL] [Abstract][Full Text] [Related]
18. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
19. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours.
Vargas PA; Cheng Y; Barrett AW; Craig GT; Speight PM
J Oral Pathol Med; 2008 May; 37(5):309-18. PubMed ID: 18248354
[TBL] [Abstract][Full Text] [Related]
20. The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors.
Sigstad E; Paus E; Bjøro T; Berner A; Grøholt KK; Jørgensen LH; Sobrinho-Simões M; Holm R; Warren DJ
Mod Pathol; 2012 Apr; 25(4):537-47. PubMed ID: 22157935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
